3693 results about "Sulfonyl" patented technology

Electroluminescent devices and materials including an electroluminescent organo-siloxane polymer. The main chain of the organo-siloxane polymer comprises an organic component that can be alkenyl, alkynyl, aralkyl, aryl, heteroaralkyl, and heteroaryl which can be substituted optionally with hydrogen, alkyl, aryl, heteroalkyl, heteroaralkyl, nitro, cyano, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, halogen, dialkylamino, diarylamino, diaralkylamino, arylamino, alkylamino, arylalkylamino, carbonyloxy, carbonylalkoxy, carbonylalkyloxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxylcarbonyloxy, sulfonyl, or sulfonyloxy. The organic component includes at least two covalent bonds coupling the organic component to the main chain of the organo-siloxane polymer. Such devices provide superior performance and mechanical stability compared with conventional organic electroluminescent materials and devices made from such materials.

Precursor materials useful for making organic electroluminescent devices such as anthracene derivatives having the structure: R40-R43 and R44-R47 are selected independently from the group consisting of hydrogen, alkyl, aryl, heteroalkyl, heteroaralkyl, nitro, cyano, hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, halogen, dialkylamino, diarylamino, diaralkylamino, arylamino, alkylamino, arylalkylamino, carbonyloxy, carbonylalkoxy, carbonylalkyloxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxylcarbonyloxy, sulfonyl, sulfonyloxy. R48 and R49 are selected independently from the group consisting of trialkoxysilyl, dialkoxysilyl, trichlorosilyl, dichlorosilyl, heptachlorotrisiloxy, and pentachlorodisiloxy.

A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae:

wherein

• [0001]
  • Base is a purine or pyrimidine base;
  [0002]
  • R¹ is OH, H, OR³, N₃, CN, halogen, including F, or CF₃, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base;
  [0003]
  • R² is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R² is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and
  [0004]
  • R³ is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

Disclosed is a carbon nanotube dispersion liquid which enables to easily form a transparent conductive film. Also disclosed is a transparent conductive film obtained by using such a carbon nanotube dispersion liquid. Specifically disclosed is a carbon nanotube dispersion liquid containing a carbon nanotube (A), a dispersing agent (B) composed of an organic compound containing one of a carboxyl group, epoxy group, amino group and sulfonyl group and having a boiling point of not less than 30˚C and not more than 150˚C, and a solvent (C). Also disclosed are a transparent conductive film containing a layer composed of a solid component of such a dispersion liquid, and a method for producing such a transparent conductive film.

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.

Disclosed are compounds of Formula 1,

wherein

• • R¹ is halogen, C₁-C₂ haloalkyl or C₁-C₂ haloalkoxy;
  • R² is H, halogen or cyano;
  • R³ is H, halogen or CF₃;
  • R⁴ is H, C₂-C₇ alkylcarbonyl or C₂-C₇ alkoxycarbonyl; and
  • R⁵ is C₁-C₆ alkyl or C₁-C₆ haloalkyl, each substituted with one substituent independently selected from hydroxy, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkylsulfinyl, C₁-C₆ alkylsulfonyl, C₂-C₇ alkylaminocarbonyl, C₃-C₉ dialkylaminocarbonyl, C₂-C₇ haloalkylaminocarbonyl and C₃-C₉ halodialkylaminocarbonyl.

Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

This invention discloses a fluorine-containing polymer and its application as ion exchange fiber material. The fluorine-containing polymer is a perfluoro resin containing sulfonylfluoride groups, and is shown in formula 1. The fluorine-containing polymer has ion exchange function, and is prepared by free radical copolymerization of perfluorosulfonyl vinyl ether, tetrafluoroethylene and hexafluoropropylene in the presence of dispersant, solvent and initiator. The dispersant/solvent is mixed solution of melamine derivative containing linear perfluoro hydrocarbon and water. The fluorine-containing polymer can be melt-spun into polymer fibers, which can be woven into fiber network that can be used as the reinforcing network material for ion exchange membranes and chlor-alkali ion membrane to reinforce and improve the ion exchange ability.

The invention relates to a 4-benzoyl pyrazole compound with herbicidal activity. The structural formula of the 4-benzoyl pyrazole compound with the herbicidal activity is as shown in specifications, wherein R1 in the structural formula is selected from hydrogen, methyl or ethyl, R2 in the structural formula is selected from methylsulfonyl, methoxyl, methylthio, fluorine, chlorine or cyan, R3 in the structural formula is selected from hydrogen, methyl, methyl fluoride, difluoromethyl or trifluoromethyl, R in the structural formula is selected from a five-membered heteroaromatic ring, a six-membered heteroaromatic ring, C1-C6 alkoxyl, aromatic hetero-oxy, six-membered aryloxy or six-membered aromatic amino, and hydrogen in the C1-C6 alkoxyl can be replaced by fluorine or chlorine; m and n are selected from 0 or 1 and cannot be 1 at the same time. A series of relatively efficient weed killers and plant growth regulators with relative good selectivity and safety are synthesized by introducing a fluorine-containing functional group to a pyrazole 3-site and chemically modifying a pyrazole 5-site.

This invention includes a process for forming a thermoplastic vulcanizate comprising: (a) admixing a C-H insertion curing agent with at least one elastomeric phase polymer to form a first admixture; (b) admixing at least one non-elastomeric polyolefin with the first admixture to form a second admixture; and (c) heating the second admixture to a temperature at least the decomposition temperature of the curing agent to crosslink the elastomeric phase while mixing the admixture to an extent sufficient to result in the formation of a thermoplastic material, hereinafter referred to as a thermoplastic vulcanizate, and optionally including an additional step (d) of shaping the resulting thermoplastic vulcanizate, especially by heating and foaming or molding the TPV. The C-H insertion curing agent is preferably selected from alkyl and aryl azides (R-N3), acyl azides (R-C(O)N3), azidoformates (R-O-C(O)-N3), sulfonyl azides (R-SO2-N3), phosphoryl azides ((RO)2-(PO)-N3), phosphinic azides (R2-P(O)-N3) and silyl azides (R3-Si-N3), with poly(sulfonyl azide) most preferred. Additionally, the invention includes a thermoplastic vulcanizate comprising a blend of: (1) an elastomeric phase crosslinked using a C-H insertion curing agent dispersed in; (2) at least one non-elastomeric thermoplastic polyolefin. The invention also includes a foamable composition comprising (1) an elastomeric phase crosslinked using a C-H insertion curing agent dispersed in; (2) at least one non-elastomeric thermoplastic polyolefin; and (3) from about 0.1 to about 25 percent by weight based on the combined weight of components (1) and (2) of at least one foaming agent as well as a fabricated part, cable jacket, cable insulation, or foam comprising the thermoplastic vulcanizate or the invention or resulting from the process of the invention.

The invention discloses a C3/C3 fluoroquinolone dimmer derivative using oxadiazole as a connection chain as well as a preparation method and an application thereof. The C3/C3 fluoroquinolone dimmer derivative using oxadiazole as a connection chain is a compound which has the following structural general formula (I), wherein R1 and R1' are independently selected from H, (C1-C10) alkyl, (C3)-(C10) cycloalkyl, (C1)-(C10) haloalkyl and substituted aryl group or substituted heterocyclic aryl group; R2 and R2' are independently selected from H, (C1-C7)alkyl, (C3)-(C7) cycloalkyl, substituted aryl group, substituted heterocyclic aryl group and hydrocarbon acyl or sulfonyl; R3 and R3' are independently selected from H, (C1-C5) alkyl, (C3)-(C5) cycloalkyl, substituted aryl radical or substitutionalheterocyclic aryl radical; and X and Y are independently selected from CH, N or carbon atoms connected with halogen, alkyl, oxyl, sulfenyl, amino, substituted amino, substituted aryl radical or substituted heterocyclic aryl radical. The C3/C3 fluoroquinolone dimmer derivative using oxadiazole as a connection chain can be used for preparing medicaments for treating tumors and preventing microbialinfection diseases.

A heat resistant negative working photosensitive composition that comprises

• • (a) one or more polybenzoxazole precursor polymers (I):
  • wherein x is an integer from about 10 to about 1000, y is an integer from 0 to about 900 and (x+y) is about less then 1000; Ar¹ is selected from the group consisting of a tetravalent aromatic group, a tetravalent heterocyclic group, or mixtures thereof; Ar² is selected from the group consisting a divalent aromatic, a divalent heterocyclic, a divalent alicyclic, a divalent aliphatic group that may contain silicon, or mixtures thereof; Ar³ is selected from the group consisting a divalent aromatic group, a divalent aliphatic group, a divalent heterocyclic group, or mixtures thereof; Ar⁴ is selected from the group consisting Ar¹ (OH)₂ or Ar²; G is an organic group selected from the group consisting groups having a carbonyl, carbonyloxy or sulfonyl group attached directly to the terminal NH group of the polymer;
  • (b) one or more photo-active compounds which release acid upon irradiation (PAGs);
  • (c) a latent crosslinker which contains at least two ˜N—(CH₂OR)_n units wherein n=1 or 2 and R is a linear or branched C₁-C₈ alkyl group, with the proviso that when a glycoluril is employed as the latent crosslinker, the G group in the polybenzoxazole precursor polymer is produced from the reaction of a cyclic anhydride; and
  • (d) at least one solvent that is not NMP.

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

The invention relates to an organic optoelectronic material, a preparation method of the organic optoelectronic material and an organic light emitting diode containing the organic material. The material is shown in the formula I, wherein R1 and R2 are respectively and independently hydrogen, halogen, cyanogroup, nitryl, isothiocyano, sulfonyl, sulfuryl, acylamino, alkyl of which the carbon atom number is 1 to 10 or alkoxy of which the carbon atom number is 1 to 12; A1 and A2 are respectively and independently phenyl, polycyclic conjugate aryl of which the carbon atom number is 10 to 60 or aromatic heterocyclic group containing at least one of N, S and O; two phenyls having groups R1 and R2 and two para-positions relative to the groups R1 and R2 are connected by directly bonding or connected through X; A1 is connected with A2 by directly bonding or through Y; X and Y are respectively and independently sulphur, oxygen, alkylene of which the carbon atom number is 1 to 6 or alkenyl of which the carbon atom number is 2 to 6; Ar1 and Ar2 are respectively and independently phenyl, cyanophenyl, alkyl benzene, polycyclic conjugate aryl of which the carbon atom number is 10 to 60 or aromatic heterocyclic group containing at least one of N, S and O.

Embodiments of the present invention are directed to a substrate for performing ionization desorption on porous silicon, methods for performing such ionization desorption and methods of making substrates. One embodiment directed to a substrate for performing ionization desorption on silicon comprises a substrate having a surface having a formula of:

As used above, X is H or Y, where at least at least twenty five mole percent of X is Y and Y is hydroxyl, or —O—R₁, or O—SiR₁, R₂, R₃ wherein R₁, R₂, and R₃ are selected from the group consisting of alkyl, alkenyl, alkynyl, aromatic, amino alkyl, amino alkenyl, amino alkynyl, pyridinyl, pyrridonyl, and carbonyl, alcohol and carboxylic acid derivatives thereof having one to twenty five atoms, and hydroxyl, amino, amide, carboxyl, ester, carbonyl, sulfhydryl, sulfonyl, phosphoral, bromo, iodo, chloro and fluoro derivatives. The letter “n” represents an integer from 1 to infinity and any vacant valences are silicon atoms, hydrogen or impurities.

The invention relates to novel ligands of 5-HT₆ receptor, to a pharmaceutical composition containing said novel ligands of 5-HT₆ receptor as active component and to novel medicaments used for humans and warm-blooded animals for treating diseases and conditions of central nervous system, in pathogenesis of which neuromediator systems induced by 5-HT₆ receptors are playing an essential role.

Azaheterocyclic compounds of the general formula 1 or racemates, or optical or geometrical isomers, or pharmaceutically acceptable salts and/or hydrates thereof are used as 5-HT₆ ligands.

Wherein R2 and R3 independently of each other represent an amino group substituent selected from hydrogen; substituted carbonyl; substituted aminocarbonyl; substituted aminothiocarbonyl; substituted sulphonyl; C₁-C₅-alkyl optionally substituted by: C₆-C₁₀-arylaminocarbonyl, heterocyclyl, C₆-C₁₀-arylaminocarbonyl, C₆-C₁₀-arylaminothiocarbonyl, C₅-C₁₀-azaheteroaryl, optionally substituted carboxyl, nitryl group, optionally substituted aryl; R¹_k represents from 1 to 3 substituents of cyclic system, independent of each other and selected from hydrogen, optionally substituted C₁-C₅-alkyl, C₁-C₅-alkoxy, C₁-C₅-alkenyl, C₁-C₅-alkynyl, halogen, trifluoromethyl, CN-group, carboxyl, optionally substituted aryl, optionally substituted heterocyclyl, substituted sulfonyl, optionally substituted carboxyl; the solid line accompanied by the dotted line represents a single or a double bond; n=1, 2 or 3.

Disclosed is a layered structure including a first electrode and a second electrode, a light-emitting layer or a charge separation layer between the first electrode and the second electrode, and a layer containing a conjugated polymer compound between the light-emitting layer or the charge separation layer and the first electrode, wherein the conjugated polymer compound contains a repeating unit selected from the group consisting of a repeating unit represented by formula (1):

wherein Ar¹ represents a divalent aromatic group, R¹ represents a substituent group having a group represented by formula (2), Ar¹ may have a substituent group other than R¹, and n1 represents an integer of 1 or more;

-(R²)_c1-(Q¹)_n2-Y¹(M¹)_a1(Z¹)_b1  (2)

wherein R² represents a divalent aromatic group which may have a substituent group, Q¹ represents a divalent organic group which may have a substituent group, Y¹ represents a carbocation, an ammonium cation, a phosphonyl cation or a sulfonyl cation, M¹ represents F⁻, Cl⁻, Br⁻, I⁻, OH⁻, R^aSO₃⁻, R^aCOO⁻, ClO⁻, ClO₂⁻, ClO₃⁻, ClO₄⁻, SCN⁻, CN⁻, NO₃⁻, SO₄²⁻, HSO₄⁻, PO₄³⁻, HPO₄²⁻, H₂PO₄⁻, BF₄⁻ or PF₆⁻, Z¹ represents a metal ion or an ammonium ion which may have a substituent group, c1 represents 0 or 1, n2 represents an integer of 0 or more, provided that n2 is 0 when c1 is 0, a1 represents an integer of 1 or more, b1 represents an integer of 0 or more, a1 and b1 are selected so that the charge of the substituent group represented by formula (2) is 0, R^a represents an alkyl group having 1 to 30 carbon atoms, which may have a substituent group, or an aryl group having 6 to 50 carbon atoms, which may have a substituent group.

The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A′), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A′) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH₂C(=0)NH₂, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—, and —CH₂CH₂CH₂CH₂—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH₂, —NH(C₁-C₆ alkyl), —N(C₁-C₆ alkyl)(C₁-C₆ alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy. (A′)X-(A)-(B)—(Z)-(L)-(D) formula (I) The compounds of the invention show activity for inhibiting LSD1, which makes them useful in the treatment or prevention of diseases such as cancer.

Provided herein are compounds of the formula (1):

as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

The present invention relates to additives for electrolytes of lithium ion secondary batteries that include one or more of the following: 1,3-propane sultone, succinic anhydride; ethenyl sulfonyl benzene, and halobenzene. It can also include biphenyl, cyclohexylbenzene; and vinylene carbonate. The weight of said 1,3-propane sultone is between 0.5 wt. % and 96.4 wt. %, said succinic anhydride is between 0.5 wt. % and 96.4 wt. %; said ethenyl sulfonyl benzene is between 0.5 wt. % and 95.2 wt. %; and said halobenzene is between 0.5 wt. % and 95.2 wt. % of the weight of the additive. Batteries with electrolytes containing said additives have improved over-charge characteristics and low temperature properties, and reduced gas generation during charging and discharging.

Disclosed is a herbicidal mixture comprising (a) at least one herbicide compound selected from the pyrimidines of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof:

wherein

• • R¹ is cyclopropyl, 4-Br-phenyl or 4-Cl-phenyl;
  • X is Cl or Br;
  • R² is H, C₁-C₁₄ alkyl, C₂-C₁₄ alkoxyalkyl, C₃-C₁₄ alkoxyalkoxyalkyl, C₂-C₁₄ hydroxyalkyl or benzyl; and
  • (b) at least one additional herbicide or herbicide safener compound selected from the group consisting of (b1) ACCase inhibitors, (b2) AHAS inhibitors, (b3) photosystem II inhibitors, (b4) photosystem I electron diverters, (b5) PPO inhibitors, (b6) EPSP synthase inhibitors, (b7) GS inhibitors, (b8) VLCFA inhibitors, (b9) auxin mimics, (b10) auxin transport inhibitors, (b11) other herbicides selected from the group consisting of flamprop-M-methyl, flamprop-M-isopropyl, difenzoquat, DSMA, MSMA, bromobutide, flurenol, cinmethylin, cumyluron, dazomet, dymron, methyldymron, etobenzanid, fosamine-ammonium, isoxaflutole, asulam, clomazone, mesotrione, metam, oxaziclomefone, oleic acid, pelargonic acid and pyributicarb, (b12) herbicide safeners selected from the group consisting of benoxacor, 1-bromo-4-[(chloromethyl)sulfonyl]benzene, cloquintocet-mexyl, cyometrinil, dichlormid, 2-(dichloromethyl)-2-methyl-1,3-dioxolane, fenchlorazole-ethyl, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen-ethyl, mefenpyr-diethyl, methoxyphenone, naphthalic anhydride and oxabetrinil, and their salts. Also disclosed is a method for controlling the growth of undesired vegetation comprising contacting the vegetation or its environment with a herbicidally effective amount of a mixture of the invention (e.g., as a composition described herein).

Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis.